SCHEMBL1107467

SCHEMBL1107467

O=C(O)C(=O)c1ccc(SC2CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPT1B Q92523 1/20 0.47
GRIK1 P39086 2/20 0.43
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
PTPRC P08575 4/20 0.37
PTPN1 P18031 4/20 0.37
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
PTPN2 P17706 1/20 0.37
CES2 O00748 4/20 0.37
CES1 P23141 3/20 0.37
PTPRF P10586 1/20 0.36
GRIN1 Q05586 2/20 0.35
GRIN2B Q13224 2/20 0.35
KMT2A Q03164 1/20 0.33
HPGD P15428 2/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GRIA2 P42262 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415667 0.84 GRIK1 (0.56) GRIK1DDB1CRBNMAOAMAOB
SCHEMBL2734194 0.83 CES2 (0.45) GRIK1DDB1CRBNMAOAMAOB
SCHEMBL2666626 0.79 GRIK1 (0.37) GRIK1DDB1CRBNMAOAMAOB
SCHEMBL15486377 0.78 PARP10 (0.44) GRIK1DDB1CRBNMAOAMAOB
SCHEMBL106314 0.78 HPGD (0.57) GRIK1DDB1CRBNMAOAMAOB
SCHEMBL28230023 0.77 KMT2A (0.51) GRIK1DDB1CRBNMAOAMAOB
SCHEMBL2744381 0.77 USP2 (0.50) GRIK1DDB1CRBNKMT2AHPGD
SCHEMBL6476599 0.76 KMT2A (0.58) GRIK1DDB1CRBNMAOAMAOB
SCHEMBL507051 0.76 KMT2A (0.58) GRIK1DDB1CRBNMAOAMAOB
SCHEMBL185319 0.75 ALDH1A1 (0.42) GRIK1MAOAGRIN1GRIN2BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340506-B2 Acetamide derivatives as glucokinase activators, their process and medicinal applications ADVINUS THERAPEUTICS LIMITED (IN) 2016-05-17 US disclosed
EP-2059522-B1 PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2014-01-08 EP disclosed
EP-2116533-B1 GLUCOKINASE ACTIVATOR KYORIN SEIYAKU KK (JP) 2013-07-10 EP disclosed
US-20120214735-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS LIMITED (IN) 2012-08-23 US disclosed
US-20120142636-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2012-06-07 US disclosed
US-20120142636-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2012-06-07 US disclosed
US-8153677-B2 Substituted pyrazolylamide compounds useful as glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-10 US disclosed
US-8153677-B2 Substituted pyrazolylamide compounds useful as glucokinase activators BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-10 US disclosed
US-7935699-B2 Pyrazole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-03 US disclosed
EP-2261216-A2 Pyrazoles as glucokinase activators F. Hoffmann-La Roche AG (CH) 2010-12-15 EP disclosed
EP-1740560-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS Prosidion Limited (GB) 2007-01-10 EP disclosed
WO-2006016194-A1 SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PROSIDION LIMITED (GB) 2006-02-16 WO disclosed
WO-2006016194-A1 SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PROSIDION LIMITED (GB) 2006-02-16 WO disclosed
WO-2006016178-A1 ENANTIOSELECTIVE PROCESS PROSIDION LIMITED (GB) 2006-02-16 WO disclosed
WO-2006016174-A1 FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE PROSIDION LIMITED (GB) 2006-02-16 WO disclosed
EP-1594867-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2005-11-16 EP disclosed
WO-2005103021-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS PROSIDION LIMITED (GB) 2005-11-03 WO disclosed
WO-2005103021-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS PROSIDION LIMITED (GB) 2005-11-03 WO disclosed
US-20040181067-A1 Tri(cyclo) substituted amide compounds OSI PHARMACEUTICALS, INC. 2004-09-16 US disclosed
WO-2004072031-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LIMITED (GB) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181067-A1 Tri(cyclo) substituted amide compounds GPR119, IAPP, SLC5A1 CPT1B 48/4885GRIK1 1416/4885DDB1 2856/4885
US-20120142636-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, PCK1 CPT1B 955/4885GRIK1 483/4885DDB1 4527/4885
US-20120214735-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS GCK, GCKR, ALDOA CPT1B 942/4885GRIK1 723/4885DDB1 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.